XDx, the Brisbane, CA-based developer of molecular diagnostics, has secured $6 million through a debt and options financing that could ultimately be worth $10 million, according to a regulatory filing. The company, founded in 2000, raised $14 million in August 2009 from a long list of backers, including Bristol-Myers Squibb, Burrill Venture Capital, Intel Capital, Kleiner Perkins Caufield & Byers, and TPG Biotechnology. The plan, stated in that announcement, was for XDx to break even in 2010. A spokesperson for the company didn’t immediately respond to a request for comment about the new debt financing.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
